BioLineRx reported second quarter 2026 revenue of $0.3 million, falling short of analyst expectations of $0.5 million. The company reported a net loss attributable to owners of $3.0 million, resulting in break-even EPS of $0.00. While royalty income from APHEXDA sales lagged forecasts, the company bolstered its balance sheet with a post-quarter $3.75 million offering and maintained its cash runway into the first half of 2027.
Key Highlights
- Royalty revenue from APHEXDA sales totaled $0.3 million for the quarter, based on $1.6 million in total product sales by commercial partners.
- Research and development expenses increased 26.5% year-over-year to $2.9 million, driven by the expansion of the GLIX1 glioblastoma clinical program.
- The Phase 1/2a trial of GLIX1 in glioblastoma is progressing as planned, with the third patient cohort expected to begin dosing in September 2026.
- Cash and equivalents stood at $13.1 million as of June 30, 2026, excluding gross proceeds from the $3.75 million financing closed in late August.